BENEFICIAL EFFECTS OF ANTENATAL MAGNESIUM SULFATE (BEAM STUDY)

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子项目和研究者（PI）可能从另一个NIH来源获得主要资金，因此可以在其他CRISP条目中表示。所列机构为中心，不一定是研究者所在机构。这是一项随机、双盲、安慰剂对照的前瞻性多中心试验，旨在研究静脉注射硫酸镁（MgS 〇 4）对降低患有胎膜早破（PROM）或早产的母亲所生儿童的死亡率或脑性麻痹（CP）发展的有效性。在早产患者入院时开始静脉输注MgSO 4，持续输注至少12小时或直至分娩，以先发生者为准。如果婴儿没有分娩，母亲出院，将在下次入院时恢复输液。将分析血液样本的总Mg、IL-1、IL-6、IL-10、TNF α、GCSF和ICAM-1。分娩时，将获得脐带样本，用于类似的测量和T4、TSH和游离T4。新生儿颅骨超声检查将在分娩后3天内进行，婴儿随访将包括6个月、12-14个月和24-28个月时的访视。主要的结局指标是婴儿死亡率或重度CP的降低。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This is a randomized, double-blind placebo controlled prospective multi-center trial designed to address the effectiveness of IV magnesium sulfate (MgS04) on reducing the incidence of death or the development of cerebral palsy (CP) in children born to mothers with premature rupture of membranes (PROM) or preterm labor. IV infusion of MgSO4 will be started on admission with preterm labor and continued for at least 12 hours or until delivery, whichever comes first. If the baby is not delivered and the mother is discharged, infusion will be resumed on the next admission. A blood sample will be analyzed for total Mg, IL-1, IL-6, IL-10, TNF alpha, GCSF and ICAM-1. At delivery a cord sample will be obtained for similar measures and T4, TSH, and free T4. Neonatal cranial ultrasounds will be performed within 3 days of delivery and infant follow-up will include visits at 6, 12-14, and 24-28 months. The primary outcome measure is a reduction in infant mortality or severe CP.